Advancing Monoclonal Antibody Manufacturing: Process Optimization, Cost Reduction Strategies, and Emerging...

Area of Science:

• Biotechnology and Biopharmaceutical Manufacturing
• Process Engineering and Optimization

Background:

• Monoclonal antibody (mAb) therapeutics are critical, necessitating efficient and cost-effective manufacturing processes.
• Current mAb production faces challenges in scalability, cost reduction, and process optimization.

Purpose of the Study:

• To review recent advancements in monoclonal antibody (mAb) manufacturing.
• To evaluate strategies for process optimization and cost reduction.
• To assess the impact of emerging technologies on mAb production efficiency.

Main Methods:

• Comprehensive literature analysis of mAb manufacturing processes.
• Examination of traditional batch, continuous, and hybrid processing systems.
• Evaluation of cost optimization techniques and emerging technologies like machine learning.

Main Results:

• Continuous processing can yield up to 35% cost savings for specific production scales.
• Hybrid facilities achieve earlier profitability (2-2.5 years sooner).
• Advanced media optimization and analytics significantly improve mAb titers and process control.

Conclusions:

• mAb manufacturing evolution presents opportunities for enhanced efficiency and reduced costs.
• Scale-dependent strategies and emerging technologies are vital for optimization.
• Future developments in continuous processing and analytics are crucial for meeting global demand.